Anna Gu1, Shweta Kamat2, Edgar Argulian3. 1. St. John's University, Queens, NY, United States. Electronic address: gus@stjohns.edu. 2. St. John's University, Queens, NY, United States. 3. Mt Sinai St. Luke's Hospital, New York, NY, United States. Electronic address: edgar.argulian@mountsinai.org.
Abstract
AIMS: The 2013 American College of Cardiology/American Heart Association Guideline defined patients with diabetes aged 40-75 years as a major statin benefit group. We explored the temporal trends and disparities in statin utilization and LDL-C levels among patients with diabetes aged 40-75 years. METHODS: A total of 4860 patients from the National Health and Nutrition Examination Survey 1999 to 2014 were included in this study. Differences in statin use and LDL-C levels were explored by patient characteristics. RESULTS: From 1999-2002 to 2011-2014, the prevalence of statin use increased from 26.2% to 49.5% (Ptrend < 0.001). This was accompanied by a continuous decrease in the mean LDL-C level (from 115.8 mg/dL to 103.3 mg/dL, Ptrend < 0.001). The use of guideline-defined high-potency statin medications (atorvastatin and rosuvastatin) remained largely unchanged (from 14.0% to 17.9%, Ptrend = 0.55). Statin utilization increased with age. Women and blacks were 10% and 16% less likely to receive statin treatment compared with men and whites, respectively. In comparison with other statin treatment, use of atorvastatin or rosuvastatin was associated with average LDL-C reduction of 8.0 mg/dL. LDL-C levels were significantly higher among women and black patients. After adjustment for potential confounders, age and Hispanic-white differences in statin use and LDL-C levels were substantially attenuated. CONCLUSIONS: Despite a steady increase in statin use during the 16-year study period, statin therapy remains underutilized in certain subgroups of patients. Confounding factors related to healthcare utilization account for some of the disparities in statin use and LDL-C levels.
AIMS: The 2013 American College of Cardiology/American Heart Association Guideline defined patients with diabetes aged 40-75 years as a major statin benefit group. We explored the temporal trends and disparities in statin utilization and LDL-C levels among patients with diabetes aged 40-75 years. METHODS: A total of 4860 patients from the National Health and Nutrition Examination Survey 1999 to 2014 were included in this study. Differences in statin use and LDL-C levels were explored by patient characteristics. RESULTS: From 1999-2002 to 2011-2014, the prevalence of statin use increased from 26.2% to 49.5% (Ptrend < 0.001). This was accompanied by a continuous decrease in the mean LDL-C level (from 115.8 mg/dL to 103.3 mg/dL, Ptrend < 0.001). The use of guideline-defined high-potency statin medications (atorvastatin and rosuvastatin) remained largely unchanged (from 14.0% to 17.9%, Ptrend = 0.55). Statin utilization increased with age. Women and blacks were 10% and 16% less likely to receive statin treatment compared with men and whites, respectively. In comparison with other statin treatment, use of atorvastatin or rosuvastatin was associated with average LDL-C reduction of 8.0 mg/dL. LDL-C levels were significantly higher among women and black patients. After adjustment for potential confounders, age and Hispanic-white differences in statin use and LDL-C levels were substantially attenuated. CONCLUSIONS: Despite a steady increase in statin use during the 16-year study period, statin therapy remains underutilized in certain subgroups of patients. Confounding factors related to healthcare utilization account for some of the disparities in statin use and LDL-C levels.
Authors: Alanna M Chamberlain; Sarah S Cohen; Jill M Killian; Keri L Monda; Susan A Weston; Ted Okerson Journal: Am J Cardiol Date: 2019-07-15 Impact factor: 2.778
Authors: M Reuel Friedman; Qimin Liu; Steven Meanley; Sabina A Haberlen; Andre L Brown; Bulent Turan; Janet M Turan; Mark Brennan-Ing; Valentina Stosor; Matthew J Mimiaga; Deanna Ware; James E Egan; Michael W Plankey Journal: Am J Public Health Date: 2022-06 Impact factor: 11.561
Authors: Angela Lowenstern; Shuang Li; Salim S Virani; Ann Marie Navar; Zhuokai Li; Jennifer G Robinson; Veronique L Roger; Anne C Goldberg; Andrew Koren; Michael J Louie; Eric D Peterson; Tracy Y Wang Journal: Am Heart J Date: 2020-04-30 Impact factor: 4.749
Authors: Robert A Riestenberg; Andrew Furman; Avery Cowen; Anna Pawlowksi; Daniel Schneider; Alana A Lewis; Sean Kelly; Babafemi Taiwo; Chad Achenbach; Frank Palella; Neil J Stone; Donald M Lloyd-Jones; Matthew J Feinstein Journal: Am Heart J Date: 2018-12-20 Impact factor: 5.099